FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1681-1683 April 15, 2004 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Blum, R. H. Related Article by The International Adjuvant Lung Cancer Trial Collaborative Group PubMed Citation

To the Editor: The International Adjuvant Lung Cancer Trial (IALT) Collaborative Group (Jan. 22 issue)¹ concludes that their study demonstrates that "cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non–small-cell lung cancer." The IALT Collaborative Group is to be commended for a study that represents an important milestone in our approach to the treatment of such patients. However, in examining Figure 2 of the article, we find that 34.5 percent of patients with stage I disease who received chemotherapy died, as compared with 35.1 percent of the control group. The corresponding rates for patients with stage II disease . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.